Epilepsy treatment agent

Abstract

Provided is a combination agent that combines N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide with an AMPA-type glutamate receptor antagonist such as 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one or 2-fluoro-6-(3-fluoro-8-oxo-7-(pyridin-3-yl)-7,8-dihydro-6H-pyrano[3,2-b:5,4-b']dipyridin-9-yl]benzonitrile and that can be possibly used as an epilepsy treatment agent.

Description

Technical field [0001] The present invention relates to a therapeutic agent for epilepsy, which combines an indan-1-ylsulfonamide derivative and an AMPA-type glutamate receptor antagonist. More specifically, the present invention relates to a therapeutic agent for epilepsy, the therapeutic agent combination N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-indene-1- Sulfonamide (or a pharmaceutically acceptable salt thereof) and AMPA type glutamate receptor antagonist. Background technique [0002] Epilepsy is one of the most common central nervous system diseases, affecting more than 50 million or more people worldwide. The WHO defines epilepsy as "a chronic brain disease of multiple etiologies characterized by excessive discharge of brain neurons (seizures), accompanied by highly variable clinical and laboratory test results." [0003] Examples of known types of seizures include partial seizures, such as simple partial seizures, complex partial seizures, and secondary generalized seiz...

AI Technical Summary

Problems solved by technology

For most conventional antiepileptic drugs, these side effects appear in a dose-dependent manner, and their composition constitutes a major problem limiting the choice and dosage of therapeutic agents

It also significantly reduces the quality of life of epilepsy patients who require long-term use of these drugs

Images